On March 30, the Food and Drug Administration (FDA) approved Triumeq PD (abacavir/dolutegravir/lamivudine) tablet

View as a webpage  /  Share May 16, 2022 Updated Resources Available: FDA-Approved HIV Medicines On March 30, the Food and Drug Administration (FDA) approved Triumeq PD (abacavir/dolutegravir/lamivudine) tablet for oral suspension, an antiretroviral drug that is used to treat HIV infection in children. The updated fact sheet lists HIV medicines approved for the treatment of HIV infection in the United States. For more information, view the FDA-Approved HIV Medicines fact sheet. Visit the Clinical Info Drug Database to learn more about approved HIV medicines, or download the Clinical Info mobile application to view the information on your Apple or Android devices. Stay Connected with HIVinfo:       SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

 

---

You are subscribed as myhcistech.healthnews360@blogger.com.  Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit the GovDelivery Subscriber Help Center at https://insights.govdelivery.com/Communications/Subscriber_Help_Center.

This service is provided in collaboration with NIH's Office of AIDS Research and HHS Office of Infectious Disease and HIV/AIDS Policy/HIV.gov.

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: HIVinfo · 8600 Rockville Pike · Bethesda, MD 20894 · 888-346-3656